Steven Powell is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1309 W 17th St Ste 101
Sioux Falls, SD 571048805
Telephone
605-328-8000Registry record last updated 17 Apr 2019.
Clinical trials
- Improving Outpatient Colonoscopy Bowel Prep With the Orton Score
Sponsor: University of Virginia
- Pembrolizumab in Combination With CRT for LA-SCCHN
Sponsor: Sanford Health
- Genetic Exploration of the Molecular Basis of Malignancy in Adults
Sponsor: Sanford Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
- Merck Sharp & Dohme LLCProgram year20231 payment
- Alkermes, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.9%Antimetabolite17.8%Hydroxyurea100%Part D<11 patientsBCL-2 Inhibitor5.9%Venclexta100%Part D<11 patients+ 3 more classes in this area
Nervous system
16.2%Atypical Antipsychotic9%Olanzapine100%Part D<11 patientsPhenothiazine7.2%Prochlorperazine Maleate100%Part D≥19 patientsSensory organs
11.5%Corticosteroid11.5%Dexamethasone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2016–2020 per NIH RePORTER. The latest:
- The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
Sanford Research/usd
FY2020$288,946P20GM103548 - The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
Sanford Research/usd
FY2019$289,592P20GM103548 - The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
Sanford Research/usd
FY2018$289,754P20GM103548
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”